title: Comparison of spantide II and CP-96,345 for blockade of tachykinin-evoked contractions of smooth muscle.
abstract: CP-96,345, a quinuclidine, is a potent inhibitor of substance P for the NK1 receptor of bovine brain, but has reduced potency for the corresponding receptor of the rat and mouse, and none for NK2 or NK3 receptors. A related quinuclidine showed similar but lower potency than CP-96,345 for NK1. CP-96,345 was more potent than the spantide I of 1984, D-Arg1,Pro2,Lys3,Pro4,Gln5,Gln6,D-Trp7,Phe8,D-Trp9, Leu10,Leu11,NH2. Our continued designs for antagonists of substance P led to spantide II in 1990 which is: D-NicLys1,Pro2,3-Pal3,Pro4,D-Cl2Phe5,Asn6,D-Trp7 ,Phe8,D-Trp9,Leu10,Nle11-NH2. The pA2 values of spantide II and CP-96,345 for guinea pig taenia coli were 7.6 and 6.8, respectively. The pIC50 values for blockade of tachykinin-mediated neurotransmission in the rabbit iris sphincter were 6.1 and 5.4, respectively. Spantide II was nearly 10 times more potent than CP-96,345 in these two assays.
authors.affiliation: Farmakologiska Institutionen, Lunds Universitet, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Håkanson
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Wang
authors.forename: K
authors.initials: K
authors.lastname: Folkers
mesh_terms: D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D007498:Iris / Q000187:drug effects / Q000502:physiology*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D011817:Rabbits; D013373:Substance P / Q000031:analogs & derivatives* / Q000494:pharmacology; D015320:Tachykinins / Q000494:pharmacology*
chemical_list: D000700:Analgesics; D001713:Biphenyl Compounds; D015320:Tachykinins; C065446:spantide II; D013373:Substance P; C066892:CP 96345